InVivo Therapeutics Holdings (FRA:04I) EV-to-EBIT : 0.77 (As of May. 21, 2024)

InVivo Therapeutics Holdings EV-to-EBIT Chart

InVivo Therapeutics Holdings Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
EV-to-EBIT		Get a 7-Day Free Trial					0.20	0.14	-0.07	0.21	0.91

InVivo Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															0.32	0.91	0.86	0.59	0.52

Competitive Comparison of InVivo Therapeutics Holdings's EV-to-EBIT

For the Biotechnology subindustry, InVivo Therapeutics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InVivo Therapeutics Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's EV-to-EBIT falls into.

InVivo Therapeutics Holdings EV-to-EBIT Calculation

InVivo Therapeutics Holdings's EV-to-EBIT for today is calculated as:

InVivo Therapeutics Holdings's current Enterprise Value is €-7.09 Mil.
InVivo Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InVivo Therapeutics Holdings  (FRA:04I) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

InVivo Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

InVivo Therapeutics Holdings's Enterprise Value for the quarter that ended in Sep. 2023 was €-4.74 Mil.
InVivo Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InVivo Therapeutics Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

InVivo Therapeutics Holdings (FRA:04I) Business Description